Access to medicines and diagnostic tests integral in the management of diabetes mellitus and cardiovascular diseases in Uganda: insights from the ACCODAD study

Table 1 Availability of all the DM and CVD medicines and diagnostic tests in all the study sites

Medicines (N = 21 classes)	Availability (%)	Diagnostic tests (N = 19)	Availability (%)
UFH	20.1	Microalbuminuria	6.8
Isosorbide mono nitrate	27.8	Serum ketones	11.4
LMWH	31.9	Serum natriuretic peptides	11.4
Intermediate insulin	34.7	Echocardiography	34.1
Hydralazine	47.2	Coagulation profile	36.4
Pre mixed insulin	60.1	Serum troponin testing	43.2
Warfarin	64.6	HbA1c testing	43.2
Soluble insulin	68.8	Thyroid function tests	43.2
ARB-thiazide diuretics	82.6	Electrocardiography	54.6
Digoxin	84.0	Uric acid testing	56.8
Statins	84.0	Lipid profile	65.9
ARB	86.8	Creatinine	86.4
Spironolactone	87.5	Urea	86.4
Benzathine penicillin	87.5	Serum electrolytes	88.6
Furosemide	89.6	Chest X-ray	88.6
Thiazide diuretics	94.4	Liver function tests	95.5
Anti platelet drugs	95.1	Glucometers	97.7
ACEI	96.5	CBC testing	97.7
Beta blockers	97.2	Urinalysis	100
CCB	99.3
OHA	100

UFH Unfractionated heparin, LMWH Low molecular weight heparin, ARB Angiotensin II receptor blockers, ACEI Angiotensin converting enzyme inhibitors, CCB Calcium channel blockers, OHA Oral hypoglycaemic agents, HbA1c Glycated haemoglobin

ISSN: 1475-9276